A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models

Molecular Pharmaceutics

Volumn 7, Issue 4, 2010, Pages 1159-1168

  Zhang, Junlin ^a   Jin, Wu ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

antitumor effect; doxorubicin; Octreotide; somatostatin receptors; sterically stabilized liposomes

Indexed keywords

DOXORUBICIN; LIPOSOME; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIPID VESICLE; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECTROFLUOROMETRY; TUMOR MODEL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRICETINAE; CRICETULUS; DOXORUBICIN; DRUG CARRIERS; HUMANS; LIPOSOMES; MALE; MICE; MICROSCOPY, CONFOCAL; NEOPLASMS; OCTREOTIDE; RATS; RECEPTORS, SOMATOSTATIN;

EID: 77955264087     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp1000235     Document Type: Article

References (45)

1. Chonn, A.; Cullis, P. R. Recent advances in liposome technologies and their applications for systemic gene delivery Adv. Drug Delivery Rev. 1998, 30, 73-83
2. Minko, T.; Pakunlu, R. I.; Wang, Y.; Khandare, J. J.; Saad, M. New generation of liposomal drugs for cancer Anti-Cancer Agents Med. Chem. 2006, 6, 537-552
3. Xiong, X. B. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic J. Controlled Release 2005, 107 (2) 262-275
4. Murphy, E. A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (27) 9343-9348
5. Â) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann. Oncol. 2004, 15 (3) 440-449
6. Harris, L. Liposome-Encapsulated Doxorubicin Compared with Conventional Doxorubicin in a Randomized Multicenter Trial as First-Line Therapy of Metastatic Breast Carcinoma Cancer 2002, 94 (1) 25-36
7. Uster, P. S.; Working, P. K.; Vaage, J. Pegylated liposomal doxorubicin (DOXILÂ, CAELYXÂ) distribution in tumour models observed with confocal laser scanning microscopy Int. J. Pharm. 1998, 162 (1-'2) 77-86
8. Vail, D. M. Pegylated liposomal doxorubicin: Proof of principle using preclinical animal models and pharmacokinetic studies Semin. Oncol. 2004, 31 (Suppl. 13) 16-35
9. Forssena, E.; Willisb, M. Ligand-targeted liposomes Adv. Drug Delivery Rev. 1998, 29, 249-271
10. Eliaz, R. E.; Francis, C.; Szoka, J. Liposome-encapsulated Doxorubicin Targeted to CD44: A Strategy to Kill CD44-overexpressing Tumor Cells Cancer Res. 2001, 61, 2592-2601
11. Lu, Y. Role of Formulation Composition in Folate Receptor-Targeted Liposomal Doxorubicin Delivery to Acute Myelogenous Leukemia Cells Mol. Pharmaceutics 2007, 4 (5) 707-712
12. Gabizon, A. In Vivo Fate of Folate-Targeted Polyethylene-Glycol Liposomes in Tumor-Bearing Mice Clin. Cancer Res. 2003, 9, 6551-6559
13. Leamon, C. P. Preclinical Antitumor Activity of a Novel Folate-Targeted Dual Drug Conjugate Mol. Pharmaceutics 2007, 4 (5) 659-667
14. Li, X.; Ding, L.; Xu, Y.; Wang, Y.; Ping, Q. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin Int. J. Pharm. 2009, 373, 116-123
15. Song, S. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo Int. J. Pharm. 2008, 363 (1-'2) 155-161
16. Alves, J. B.; et al. Local delivery of EGF-liposome mediated bone modeling in orthodontic tooth movement by increasing RANKL expression. Life Sci., in press.
17. Yokoe, J.-i. Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats Int. J. Pharm. 2008, 353, 28-34
18. Reubi, J. C.; Kvols, L.; Krenning, E.; Lamberts, S. W. J. Distribution of somatostantin receptors in normal and tumor tissue Metabolism 1990, 39 (Suppl. 2) 78-81
19. Volante, M. Somatostatin, cortistatin and their receptors in tumours Mol. Cell. Endocrinol. 2008, 286, 219-229
20. Olsen, J. O. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan) Semin. Nucl. Med. 1995, 25 (3) 251-261
21. Engel, J. B.; Schally, A. V.; Dietl, J.; Rieger, L.; Hönig, A. Targeted Therapy of Breast and Gynecological Cancers with Cytotoxic Analogues of Peptide Hormones Mol. Pharmaceutics 2007, 4 (5) 652-658
22. Nagy, A. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 1794-1799
23. Kiaris, H. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice Eur. J. Cancer 2001, 37, 620-628
24. Shen, H. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice Eur. J. Pharmacol. 2008, 60 (1-'3) 23-29
25. Huang, C.-M.; Wu, Y.-T.; Chen, S.-T. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis Chem. Biol. 2000, 7 (7) 453-461
26. Moody, T. W. Camptothecin-somatostatin conjugates inhibit the growth of small cell lung cancer cells Peptides 2005, 26 (9) 1560-1566
27. Sun, L.-C.; Luo, J.; Mackey, L. V.; Fuselier, J. A.; Coy, D. H. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, αVΒ3/αVΒ5 and MMP-2/-9 Cancer Lett. 2007, 246 (1-'2) 157-166
28. Na, D. H. Identification of the Modifying Sites of Mono-Pegylated Salmon Calcitonins by Capillary Electrophoresis and MALDI-TOF Mass Spectrometry J. Chromatogr., B: Biomed. Sci. Appl. 2001, 754 (1) 259-263
29. Na, D. H.; Lee, K. C.; DeLuca, P. P. PEGylation of Octreotide: II. Effect of N-terminal Mono-PEGylation on Biological Activity and Pharmacokinetics Pharm. Res. 2005, 22, 5, 743-749
30. Na, D. H.; DeLuca, P. P. PEGylation of Octreotide- I. Separation of Positional Isomers and Stability Against Acylation by Poly(D, L-lactide-co-glycolide) Pharm. Res. 2005, 22, 5, 736-742
31. Tang, N. Improving Penetration in Tumors With Nanoassemblies of Phospholipids and Doxorubicin J. Natl. Cancer Inst. 2007, 99, 13
32. Kobayashi, T. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells Int. J. Pharm. 2007, 329, 94-102
33. Hu, F.-Q.; Wu, X.-l.; Du, Y.-Z.; You, J.; Yuan, H. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin Eur. J. Pharm. Biopharm. 2008, 69, 117-125
34. Garga, A.; Tisdalea, A. W.; Haidarib, E.; Kokkoli, E. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide Int. J. Pharm. 2009, 366, 201-210
35. Blumenthal, R. D. In Vitro Assays; Humana Press Inc.: Totowa, NJ, 2005; Vol. 1, p 69 -' 78.
36. Fundaro, A. Nonstealth and stealth solid lipid nanoparticles SLN carrying doxorubicin pharmacokinetics and tissue distribution after iv administration to rats Pharmacol. Res. 2000, 42 (4) 337-343
37. Peng, L. Combinatorial chemistry identifies high-affinity peptidomimetics against a4b1 integrin for in vivo tumor imaging Nat. Chem. Biol. 2006, 2, 7
38. Ogawara, K.-i.; Un, K.; Tanaka, K.-i.; Higaki, K.; Kimura, T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells J. Controlled Release 2009, 133, 4-10
39. 3]octreotide labels human somatostatin sst2 and sst5 receptors Eur. J. Pharmacol. 1998, 348, 2-3
40. Xu, B. Expression of somatostatin receptor subtype 2 in 12 tumor cell lines Guangdong Med. J. 2006, 27, 3
41. Watt, H. L.; Kumar, U. Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells Cancer Cell Int. 2006, 6, 5-23
42. Ahmad, I.; Allen, T. M. Antibody-mediated Specific Binding and Cytotoxicity of Liposome-entrapped Doxorubicin to Lung Cancer Cells in Vitro Cancer Res. 1992, 52, 4817-4820
43. Mizuno, T.; Mohri, K.; Nasu, S.; Danjo, K.; Okamoto, H. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence J. Controlled Release 2009, 134, 149-154
44. Kirchherr, A.-K.; Briel, A.; Mad̈er, K. Stabilization of Indocyanine Green by Encapsulation within Micellar Systems Mol. Pharmaceutics 2009, 6, 2, 480-491
45. Ohashi, K.; Kabasawa, T.; Ozeki, T.; Okada, H. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Controlled Release 2009, 135, 19-24